Liposomal dual delivery systems in visceral leishmaniasis enhance the synergistic effects of combination therapy: A promise for the future

Abstract

Visceral leishmaniasis (VL) is a neglected tropical disease, and this review has summarized the current treatment scenario and its prospects. It also highlights alternative approaches used by research groups in India and around the world to develop cutting-edge and potent anti-leishmanial treatments. Even though numerous medications could be utilized to treat VL, the limitations of current treatments including their toxicity, cost, route of administration, and duration of doses, have contributed to the emergence of resistance. Combination therapy might be a better option due to its shorter duration, easier route of administration, and ability to extend the lifespan of individual drugs. However, there is a risk of not delivering both the drugs to the target site together, which can be overcome by the liposomal entrapment of those drugs and at a time knock an opportunity to reduce the dosage of amphotericin B if the combination drug provides a synergistic effect with it. Therefore, this review presents a novel strategy to fight against VL by introducing dual drug-loaded liposomes.

Keywords

Visceral leishmaniasis / Liposomal anti-leishmanial drug / Dual drug liposome

References

[1] Studentsky L, Laor O, Fouad A, Irina BA, Debora D, et al. Leishmania donovani transmission cycle associated with human infection, Phlebotomus alexandri sand flies, and hare blood meals, Israel. Emerg Infect Dis 2023; 29(5): 945.

[2] Gopu B, Parampreet K, Ramajayan P, Kuljit S. Insights into the drug screening approaches in leishmaniasis. Int Immunopharmacol 2023; 114: 109591.

[3] WHO . A report on visceral leishmaniasis as neglected tropical disease. [Online]. Available from: https://www.who.int/news-room/fact-sheets/detail/leishmaniasis. [Accessed on 3 May 2022].

[4] Vikas K, Kaur S. Lymphatic filariasis and visceral leishmaniasis coinfection: A review on their epidemiology, therapeutic, and immune responses. Acta Trop 2021; 224: 106117.

[5] van Griensven J, Dorlo TPC, Diro E, Costa C, Burza S. The status of combination therapy for visceral leishmaniasis: An updated review. Lancet Infect Dis 2024; 1(1): e36-e46.

[6] Ahmed M, Mbui J, Mohammed R, Olobo J, Ritmeijer K, Alcoba G, et al. Paromomycin and miltefosine combination as an alternative to treat patients with visceral leishmaniasis in eastern Africa: A randomized, controlled, multicountry trial. Clin Infect Dis 2023; 3(3): e1177-e1185.

[7] Sundar S, Singh J, Dinkar A, Agrawal N. Safety and effectiveness of miltefosine in post-Kala-Azar dermal leishmaniasis: An observational study. Open Forum Infect Dis 2023; 10(5): ofad231.

[8] Frézard F, Aguiar MMG, Ferreira LAM, Ramos GS, Santos TT, Borges GSM, et al. Liposomal amphotericin B for treatment of leishmaniasis: From the identification of critical physicochemical attributes to the design of effective topical and oral formulations. Pharmaceutics 2022; 15(1): 99.

[9] Hassan MA, Omar AA, Mohamed IA, Garba B, Fuje MMA, Salad SO. A late diagnosis of visceral leishmaniasis using tru-cut biopsy of the spleen and malaria co-infection-A diagnostic challenge: A case report in Somalia. Infect Drug Resist 2023; 16: 6513-6519.

[10] National Center for Vector Borne Diseases Control. A report on visceral leishmaniasis; 2023. [Online]. Available from: https://nvbdcp.gov.in. [Accessed on 15 January 2023].

[11] Elmahallawy EK, Alkhaldi AAM. Insights into Leishmania molecules and their potential contribution to the virulence of the parasite. Vet Sci 2021; 8(2): 33.

[12] Kupani M, Pandey RK, Mehrotra S. Neutrophils and visceral leishmaniasis: Impact on innate immune response and cross-talks with macrophages and dendritic cells. J Cell Physiol 2021; 236(4): 2255-2267.

[13] Kumari D, Singh K. Exploring the paradox of defense between host and Leishmania parasite. Int Immunopharmacol 2022; 102: 108400.

[14] Pacheco-Fernandez T, Volpedo G, Verma C, Satoskar AR. Understanding the immune responses involved in mediating protection or immunopathology during leishmaniasis. Biochem Soc Trans 2021; 1(1): 297-311.

[15] Carreira JCA, da Silva. The role of neutrophils in the interaction with Leishmania: Far beyond a simple Trojan Horse? Open J Animal Sci 2021; 3(3): 399-421.

[16] Gupta M, Pathak A, Pathak YV, Gupta S. Introduction to pharmacology of macrophages with drug delivery perspective. Macrophage targeted delivery systems. In: Gupta S, Pathak YV, eds. Cham: Springer; 2022, p. 3-29.

[17] Quarleri J, Cevallos C, Delpino MV. Apoptosis in infectious diseases as a mechanism of immune evasion and survival. Adv Protein Chem Struct Biol 2021; 125: 1-24.

[18] Su Y, Gao J, Kaur P, Wang Z. Neutrophils and macrophages as targets for development of nanotherapeutics in inflammatory diseases. Pharmaceutics 2020; 12(12): 1222.

[19] Pérez-Figueroa E, Álvarez-Carrasco P, Ortega E, Maldonado-Bemal C. Neutrophils: Many ways to die. Front Immunol 2021; 12: 631821.

[20] Mahor H, Mukherjee A, Sarkar A, Saha B. Anti-leishmanial therapy: Caught between drugs and immune targets. Exp Parasitol 2023; 245: 108441.

[21] Costa-da-Silva AC, Nascimento DO, Ferreira JRM, Guimaraes-Pinto K, Freire-de-Lima L, Morrot A, et al. Immune responses in leishmaniasis: An overview. Trop Med Infect Dis 2022; 7(4): 54.

[22] Bogdan C. Macrophages as host, effector and immunoregulatory cells in leishmaniasis: Impact of tissue micro-environment and metabolism. Cytokine X 2020; 2(4): 100041.

[23] Loria-Cervera EN, Andrade-Narvaez F. The role of monocytes/ macrophages in Leishmania infection: A glance at the human response. Acta Trop 2020; 207: 105456.

[24] Carneiro MB, Vaz LG, Afonso LCC, Horta MF, Vieira LQ. Regulation of macrophage subsets and cytokine production in leishmaniasis. Cytokine 2021; 147: 155309.

[25] Tomiotto-Pellissier F, Bortoleti BTDS, Assolini JP, Gonsalves MD, Carloto ACM, Miranda-Sapla MM, et al. Macrophage polarization in leishmaniasis: Broadening horizons. Front Immunol 2018; 9: 2529.

[26] Kim SY, Nair MG. Macrophages in wound healing: Activation and plasticity. Immunol Cell Biol 2019; 3(3): 258-267.

[27] Chauhan P, Shukla D, Chattopadhyay D, Saha B. Redundant and regulatory roles for toll-like receptors in Leishmania infection. Clin Exp Immunol 2017; 190(2): 167-186.

[28] Duan T, Du Y, Xing C, Wang HY, Wang RF. Toll-like receptor signaling and its role in cell-mediated immunity. Front Immunol 2022; 13: 812774.

[29] Wijnant GJ, Dumetz F, Dirkx L, Bulte D, Cuypers B, Van Bocxlaer K. Drug resistance and other causes of treatment failure in leishmaniasis. Front Trop Dis 2022; 3: 837460.

[30] Sundar S. Drug resistance in Indian visceral leishmaniasis. Trop Med Int Health 2001; 11(11): 849-854.

[31] Yadagiri G, Singh A, Arora K, Mudavath SL. Immunotherapy and immunochemotherapy in combating visceral leishmaniasis. Front Med 2023; 10: 1096458.

[32] Croft SL, Engel J. Miltefosine discovery of the antileishmanial activity of phospholipid derivatives. Trans R Soc Trop Med Hyg 2006; 100(Suppl 1): S4-S8.

[33] Canuto GA, Castilho-Martins EA, Tavares M, Lopez-Gonzalvez A, Rivas L, Barbas C. CE-ESI-MS metabolic fingerprinting of Leishmania resistance to antimony treatment. Electrophoresis 2012; 33(12): 1901-1910.

[34] Singh AK, Papadopoulou B, Ouellette M. Gene amplification in amphotericin B-resistant Leishmania tarentolae. Exp Parasitol 2001; 3(3): 141-147.

[35] Bulte D, Van Bockstal L, Dirkx L, Van den Kerkhof M, De Trez C, Timmermans JP, et al. Miltefosine enhances infectivity of a miltefosine-resistant Leishmania infantum strain by attenuating its innate immune recognition. PLoS Negl Trop Dis 2021; 15(7): e0009622.

[36] Deep DK, Singh R, Bhandari V, Verma A, Sharma V, Wajid S, et al. Increased miltefosine tolerance in clinical isolates of Leishmania donovani is associated with reduced drug accumulation, increased infectivity and resistance to oxidative stress. PLoS Negl Trop Dis 2017; 11(6): e0005641.

[37] Capela R, Moreira R, Lopes F. An overview of drug resistance in protozoal diseases. Int J Mol Sci 2019; 20(22): 5748.

[38] Marques SA, Merlotto MR, Ramos PM, Marques MEA. American tegumentary leishmaniasis: Severe side effects of pentavalent antimonial in a patient with chronic renal failure. An Bras Dermatol 2019; 3(3): 355-357.

[39] Hamill RJ. Amphotericin B formulations: A comparative review of efficacy and toxicity. Drugs 2013; 9(9): 919-934.

[40] Sundar S, Jha TK, Thakur CP, Sinha PK, Bhattacharya SK. Injectable paromomycin for visceral leishmaniasis in India. N Engl J Med 2007; 25(25): 2571-2781.

[41] Armijos RX, Weigel MM, Calvopina M, Mancheno M, Rodriguez R. Comparison of the effectiveness of two topical paromomycin treatments versus meglumine antimoniate for New World cutaneous leishmaniasis. Acta Trop 2004; 2(2): 153-160.

[42] Musa AM, Younis B, Fadlalla A, Royce C, Balasegaram M, Wasunna M, et al. Paromomycin for the treatment of visceral leishmaniasis in Sudan: A randomized, open-label, dose-finding study. PLoS Negl Trop Dis 2010; 4(10): e855.

[43] Sundar S, Chakravarty J. Liposomal amphotericin B and leishmaniasis: Dose and response. J Glob Infect Dis 2010; 2(2): 159-166.

[44] Olliaro PL. Drug combinations for visceral leishmaniasis. Curr Opin Infect Dis 2010; 6(6): 595-602.

[45] Van Griensven J, Diro E. Visceral leishmaniasis: Recent advances in diagnostics and treatment regimens. Infect Dis Clin North Am 2019; 1(1): 79-99.

[46] Sundar S, Singh OP, Chakravarty J. Visceral leishmaniasis elimination targets in India, strategies for preventing resurgence. Expert Rev Anti Infect Ther 2018; 11(11): 805-812.

[47] Corral MJ, Gonzalez-Sanchez E, Cuquerella M, Alunda JM. In vitro synergistic effect of amphotericin B and allicin on Leishmania donovani and Linfantum. Antimicrob Agents Chemother 2014; 3(3): 1596-1602.

[48] Ferreira C, Soares DC, Nascimento MT, Pinto-da-Silva LH, Sarzedas CG, Tinoco LW, et al. Resveratrol is active against Leishmania amazonensis: In vitro effect of its association with amphotericin B. Antimicrob Agents Chemother 2014; 10(10): 6197-6208.

[49] Goswami RP, Rahman M, Das S, Tripathi SK, Goswami RP. Combination therapy against Indian visceral leishmaniasis with liposomal amphotericin B (FungisomeTM) and short-course miltefosine in comparison to miltefosine monotherapy. Am J Trop Med Hyg 2020; 1(1): 308-314.

[50] Diro E, Blesson S, Edwards T, Ritmeijer K, Fikre H, Admassu H, et al. A randomized trial of AmBisome monotherapy and AmBisome and miltefosine combination to treat visceral leishmaniasis in HIV co-infected patients in Ethiopia. PLoS Negl Trop Dis 2019; 13(1): e0006988.

[51] Fura JM, Sarkar S, Pidgeon SE, Pires MM. Combatting bacterial pathogens with immunomodulation and infection tolerance strategies. Curr Top Med Chem 2017; 3(3): 290-304.

[52] Broide DH. Immunomodulation of allergic disease. Annu Rev Med 2009; 60: 279-291.

[53] Strzelec M, Detka J, Mieszczak P, Sobocinska MK, Majka M. Immunomodulation a general review of the current state-of-the-art and new therapeutic strategies for targeting the immune system. Front Immunol 2023; 14: 1127704.

[54] Locy H, de Mey S, de Mey W, De Ridder M, Thielemans K, Maenhout SK. Immunomodulation of the tumor microenvironment: Turn foe into friend. Front Immunol 2018; 9: 2909.

[55] Ratna A, Arora SK. Immunomodulators as therapeutic option in parasitic infections. J Bacteriol Vaccin Res 2018; 1(1): 1002.

[56] Salem MM, Werbovetz KA. Natural products from plants as drug candidates and lead compounds against leishmaniasis and trypanosomiasis. Curr Med Chem 2006; 21(21): 2571-2598.

[57] Polonio T, Efferth T. Leishmaniasis: Drug resistance and natural products (review). Int J Mol Med 2008; 3(3): 277-286.

[58] Bhattacharjee S, Gupta G, Bhattacharya P, Mukherjee A, Mujumdar SB, Pal A, et al. Quassin alters the immunological patterns of murine macrophages through generation of nitric oxide to exert antileishmanial activity. J Antimicrob Chemother 2009; 2(2): 317-324.

[59] Sen R, Ganguly S, Saha P, Chatterjee M. Efficacy of artemisinin in experimental visceral leishmaniasis. Int Antimicrob Agents 2010; 1(1): 43-49.

[60] Haldar AK, Sen P, Roy S. Use of antimony in the treatment of leishmaniasis: Current status and future directions. Mol Biol Int 2011; 2011: 571242.

[61] Bhattacharjee S, Majumder N, Bhattacharyya P, Bhattacharyya S, Majumdar S. Immunomodulatory role of arabinosylated lipoarabinomannan on Leishmania donovani infected murine macrophages. Indian J Biochem Biophys 2007; 5(5): 366-372.

[62] Bhattacharjee S, Bhattacharjee A, Majumder S, Majumdar SB, Majumdar S. Glycyrrhizic acid suppresses COX-2-mediated anti-inflammatory responses during Leishmania donovani infection. J Antimicrob Chemother 2012; 8(8): 1905-1914.

[63] Roy N, Ghosh S, Juin SK, Ghosh R, Majumdar SB, Majumdar S. Immunomodulator mediated changes in plasma membrane calcium ATPase in controlling visceral leishmaniasis. Exp Parasitol 2020; 217: 107948.

[64] Charan RMR, Velappan AB, Chellappan D, Debnath J, Kar Mahapatra S. Eugenol derived immunomodulatory molecules against visceral leishmaniasis. Eur J Med Chem 2017; 139: 503-518.

[65] Debnath J, Kar Mahapatra S, Narayanan S, Shandil RK, Potluri V, Charan Raja MR, et al. Compositions of eugenol derivatives for treatment of visceral leishmaniasis. 2019 International publication No: WO 2019/030643A1.

[66] Charan RMR, Kar A, Srinivasan S, Chellappan D, Debnath J, Kar MS. Oral administration of eugenol oleate cures experimental visceral leishmaniasis through cytokines abundance. Cytokine 2021; 145: 155301.

[67] Dalton JE, Kaye PM. Immunomodulators: Use in combined therapy against leishmaniasis. Expert Rev Anti Infect Ther 2010; 7(7): 739-742.

[68] Kar A, Jayaraman A, Charan Raja MR, Srinivasan S, Debnath J, Mahapatra SK. Synergic effect of eugenol oleate with amphotericin B augments anti-leishmanial immune response in experimental visceral leishmaniasis in vitro and in vivo. Int Immunopharmacol 2021; 91: 107291.

[69] Kar A, Jayaraman A, Kumar A, Kar MS. Dynamicity in host metabolic adaptation is influenced by the synergistic effect of eugenol oleate and amphotericin B during Leishmania donovani infection in vitro. Front Cell Infect Microbiol 2021; 11: 709316.

[70] Bangham AD. Liposomes: The Babraham connection. Chem Phys Lipids 1993; 64(1-3): 275-285.

[71] Kakoli S, Shubhadeep B, Mahitosh M. Liposome as a drug delivery system. In, Prokopovich P, eds. Biological and pharmaceutical applications of nanomaterials. Boca Raton: CRC press publishers; 2019,p. 53-100.

[72] Bangham AD, Standish MM, Weissmann G. The action of steroids and streptolysin S on the permeability of phospholipid structures to cations. J Mol Biol 1965; 1(1): 253-259.

[73] Akbarzadeh A, Rezaei-Sadabady R, Davaran S, Joo SW, Zarghami N, Hanifehpour Y, et al. Liposome: Classification, preparation, and applications. Nanoscale Res Lett 2013; 8(1): 102.

[74] Shashi K, Satinder K, Bharat P. A complete review on liposome. Int Res J Pharm 2012; 7(7): 10-16.

[75] Alving CR, Steck EA, Hanson WL, Loizeaux PS, Chapman WL Jr. , Waits VB. Improved therapy of experimental leishmaniasis by use of a liposome-encapsulated antimonial drug. Life Sci 1978; 22(12): 1021-1026.

[76] Alving CR, Steck EA, Chapman WL Jr. , Waits VB, Hendricks LD, Swartz GM Jr. , et al. Therapy of leishmaniasis: Superior efficacies of liposome-encapsulated drugs. Proc Natl Acad Sci U S A 1978; 6(6): 2959-2963.

[77] Alving CR, Steck EA, Chapman WL Jr. , Waits VB, Hendricks LD, Swartz GM Jr. , et al. Liposomes in leishmaniasis: Therapeutic effects of antimonial drugs, 8-aminoquinolines, and tetracycline. Life Sci 1980; 26(26): 2231-2238.

[78] Alving CR, Swartz GM Jr. , Hendricks LD, Chapman WL Jr. , Waits VB, Hanson WL. Liposomes in leishmaniasis: Effects of parasite virulence on treatment of experimental leishmaniasis in hamsters. Ann Trop Med Parasitol 1984; 3(3): 279-286.

[79] Alving CR. Liposomes as drug carriers in leishmaniasis and malaria. Parasitol Today 1986; 4(4): 101-107.

[80] Weldon JS, Munnell JF, Hanson WL, Alving CR. Liposomal chemotherapy in visceral leishmaniasis: An ultrastructural study of an intracellular pathway. Z Parasitenkd 1983; 4(4): 415-424.

[81] Chapman WL Jr. , Hanson WL, Alving CR, Hendricks LD. Antileishmanial activity of liposome-encapsulated meglumine antimonate in the dog. Am J Vet Res 1984; 45(5): 1028-1030.

[82] Berman JD, Hanson WL, Chapman WL, Alving CR, Lopez-Berestein G. Antileishmanial activity of liposome-encapsulated amphotericin B in hamsters and monkeys. Antimicrob Agents Chemother 1986; 6(6): 847-851.

[83] New RRC, Chance ML, Heath S. Liposome therapy for experimental cutaneous and visceral leishmaniasis. Biol Cell 1983; 47: 59-64.

[84] Frézard F, Michalick MS, Soares CF, Demicheli C. Novel methods for the encapsulation of meglumine antimoniate into liposomes. Braz J Med Biol Res 2000; 7(7): 841-846.

[85] Schettini DA, Ribeiro RR, Demicheli C, Rocha OG, Melo MN, Michalick MS, et al. Improved targeting of antimony to the bone marrow of dogs using liposomes of reduced size. Int J Pharm 2006; 315(1-2): 140-147.

[86] Frézard F, Demicheli C, Ribeiro RR. Pentavalent antimonials: New perspectives for old drugs. Molecules 2009; 7(7): 2317-2336.

[87] Kalat SA, Khamesipour A, Bavarsad N, Fallah M, Khashayarmanesh Z, Feizi E, et al. Use of topical liposomes containing meglumine antimoniate (Glucantime) for the treatment of Lmajor lesion in BALB/c mice. Exp Parasitol 2014; 143: 5-10.

[88] Sinha R, Roychoudhury J, Palit P, Ali N. Cationic liposomal sodium stibogluconate (SSG), a potent therapeutic tool for treatment of infection by SSG-sensitive and -resistant Leishmania donovani. Antimicrob Agents Chemother 2015; 1(1): 344-355.

[89] Momeni A, Rasoolian M, Momeni A, Navaei A, Emami S, Shaker Z, et al. Development of liposomes loaded with anti-leishmanial drugs for the treatment of cutaneous leishmaniasis. J Liposome Res 2013; 2(2): 134-144.

[90] Papagiannaros A, Bories C, Demetzos C, Loiseau PM. Antileishmanial and trypanocidal activities of new miltefosine liposomal formulations. Biomed Pharmacother 2005; 10(10): 545-550.

[91] Bray PG, Barrett MP, Ward SA, de Koning HP. Pentamidine uptake and resistance in pathogenic protozoa: Past, present and future. Trends Parasitol 2003; 5(5): 232-239.

[92] Hammarton TC, Mottram JC, Doerig C. The cell cycle of parasitic protozoa: Potential for chemotherapeutic exploitation. Prog Cell Cycle Res 2003; 5: 91-101.

[93] Minodier P, Parola P. Cutaneous leishmaniasis treatment. Travel Med Infect Dis 2007; 3(3): 150-158.

[94] Nylén S, Gautam S. Immunological perspectives of leishmaniasis. J Glob Infect Dis 2010; 2(2): 135-146.

[95] Bodhe PV, Kotwani RN, Kirodian BG, Pathare AV, Pandey AK, Thakur CP, et al. Dose-ranging studies on liposomal amphotericin B (L-AMP-LRC-1) in the treatment of visceral leishmaniasis. Trans R Soc Trop Med Hyg 1999; 3(3): 314-318.

[96] Amato VS, Rabello A, Rotondo-Silva A, Kono A, Maldonado TP, Alves IC, et al. Successful treatment of cutaneous leishmaniasis with lipid formulations of amphotericin B in two immunocompromised patients. Acta Trop 2004; 2(2): 127-132.

[97] Sundar S, Chakravarty J. Paromomycin in the treatment of leishmaniasis. Expert Opin Investig Drugs 2008; 5(5): 787-794.

[98] Chattopadhyay A, Jafurulla M. A novel mechanism for an old drug: Amphotericin B in the treatment of visceral leishmaniasis. Biochem Biophys Res Commun 2011; 416(1-2): 7-12.

[99] Stone NR, Bicanic T, Salim R, Hope W. Liposomal amphotericin B [amBisome(®)]: A review of the pharmacokinetics, pharmacodynamics, clinical experience and future directions. Drugs 2016; 4(4): 485-500.

[100] Zielińn ska J, Wieczór M, Bączek T, Gruszecki M, Czub J. Thermodynamics and kinetics of amphotericin B self-association in aqueous solution characterized in molecular detail. Sci Rep 2016; 6: 19109.

[101] Ghosh J, Das S, Guha R, Ghosh D, Naskar K, Das A, et al. Hyperlipidemia offers protection against Leishmania donovani infection: role of membrane cholesterol. J Lipid Res 2012; 12(12): 2560-2572.

[102] Asad M, Bhattacharya P, Banerjee A, Ali N. Therapeutic and immunomodulatory activities of short-course treatment of murine visceral leishmaniasis with KALSOME™10, a new liposomal amphotericin B. BMC Infect Dis 2015; 15: 188.

[103] Borborema SE, Schwendener RA, Osso JA Jr. , de Andrade HF Jr. , do Nascimento N. Uptake and antileishmanial activity of meglumine antimoniate-containing liposomes in Leishmania (Leishmania) major-infected macrophages. Int J Antimicrob Agents 2011; 4(4): 341-347.

[104] Peine KJ, Gupta G, Brackman DJ, Papenfuss TL, Ainslie KM, Satoskar AR, et al. Liposomal resiquimod for the treatment of Leishmania donovani infection. J Antimicrob Chemother 2014; 1(1): 168-175.

[105] Romanelli MM, da Costa-Silva TA, Cunha-Junior E, Dias Ferreira D, Guerra JM, Galisteo AJ Jr. , et al. Sertraline delivered in phosphatidylserine liposomes is effective in an experimental model of visceral leishmaniasis. Front Cell Infect Microbiol 2019; 9: 353.

[106] Mukherjee S, Pradhan S, Ghosh S, Sundar S, Das S, Mukherjee B, et al. Short-course treatment with imipramine entrapped in squalene liposomes results in sterile cure of experimental visceral leishmaniasis induced by antimony resistant Leishmania donovani with increased efficacy. Front Cell Infect Microbiol 2020; 10: 595415.

[107] Oliva G, Gradoni L, Ciaramella P, De Luna R, Cortese L, Orsini S, et al. Activity of liposomal amphotericin B (AmBisome) in dogs naturally infected with Leishmania infantum. J Antimicrob Chemother 1995; 6(6): 1013-1019.

[108] Ribeiro RR, Moura EP, Pimentel VM, Sampaio WM, Silva SM, Schettini DA, et al. Reduced tissue parasitic load and infectivity to sand flies in dogs naturally infected by Leishmania (Leishmania) chagasi following treatment with a liposome formulation of meglumine antimoniate. Antimicrob Agents Chemother 2008; 7(7): 2564-2572.

[109] Pal S, Ravindran R, Ali N. Combination therapy using sodium antimony gluconate in stearylamine-bearing liposomes against established and chronic Leishmania donovani infection in BALB/c mice. Antimicrob Agents Chemother 2004; 9(9): 3591-3593.

[110] Banerjee A, De M, Ali N. Complete cure of experimental visceral leishmaniasis with amphotericin B in stearylamine-bearing cationic liposomes involves down-regulation of IL-10 and favorable T cell responses. J Immunol 2008; 2(2): 1386-1398.

[111] Cauchetier E, Paul M, Rivollet D, Fessi H, Astier A, Deniau M. Therapeutic evaluation of free and nanocapsule-encapsulated atovaquone in the treatment of murine visceral leishmaniasis. Ann Trop Med Parasitol 2003; 3(3): 259-268.

[112] Proulx ME, Desormeaux A, Marquis JF, Olivier M, Bergeron MG. Treatment of visceral leishmaniasis with sterically stabilized liposomes containing camptothecin. Antimicrob Agents Chemother 2001; 9(9): 2623-2627.

[113] New RR, Chance ML, Heath S. Antileishmanial activity of amphotericin and other antifungal agents entrapped in liposomes. J Antimicrob Chemother 1981; 5(5): 371-381.

[114] Fidler IJ, Schroit AJ. Recognition and destruction of neoplastic cells by activated macrophages: Discrimination of altered self. Biochim Biophys Acta 1988; 2(2): 151-173.

[115] Tempone AG, Perez D, Rath S, Vilarinho AL, Mortara RA, de Andrade HF Jr. Targeting Leishmania (L. ) chagasi amastigotes through macrophage scavenger receptors: The use of drugs entrapped in liposomes containing phosphatidylserine. J Antimicrob Chemother 2004; 1(1): 60-68.

[116] Yadav D, Sandeep K, Pandey D, Dutta RK. Liposomes for drug delivery. J Biotechnol Biomater 2017; 7: 276.